Copyright
©The Author(s) 2016.
World J Exp Med. Feb 20, 2016; 6(1): 21-36
Published online Feb 20, 2016. doi: 10.5493/wjem.v6.i1.21
Published online Feb 20, 2016. doi: 10.5493/wjem.v6.i1.21
Society | Target population | Target population |
APASL, 2010 | Chronic hepatitis | Cirrhosis |
No recommendation | HBV and HCV cirrhosis | |
AASLD, 2011 | HBV-positive patients | HBV and/or HCV cirrhotics |
Male Asian HBV+ > 40 yr | Fourth stage PBC | |
African > 20 yr; Familial predisposition + for HCC | a1-antitrypsin deficit | |
Autoimmune hepatitis | ||
NASH | ||
JSH, 2011 | HBV and HCV chronic hepatitis | Non viral cirrhosis |
HBV and HCV cirrhosis | ||
EASL, 2012 | HBV + active hepatitis | Child A and B cirrhosis |
HCV + hepatitis with advanced fibrosis F3 (Metavir) | Child C cirrhosis with indication to liver transplantation |
- Citation: Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36
- URL: https://www.wjgnet.com/2220-315X/full/v6/i1/21.htm
- DOI: https://dx.doi.org/10.5493/wjem.v6.i1.21